Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol

Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol

Abstract Background Neoadjuvant chemotherapy is used in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) to increase resection rate and improve cancer outcome. However, there is a need for better prediction of resectability. The aim of this prospective, si...

Full description

Saved in:
Bibliographic Details
Main Authors: Luís Filipe Abreu de Carvalho, Filip Gryspeerdt, Wim Ceelen, Karen Geboes, Suzane Ribeiro, Anne Hoorens, Nele Vandenbussche, Kathleen B.M. Claes, Clarisse Lecluyse, Aliaksandr Anisau, Johan Van Ongeval, Willem Lybaert, Lars Triest, Andrew Vervaecke, Steven Sas, Barbara Claerhout, Carolien Beyls, Mark Sie, Frederik Berrevoet
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Surgery
Subjects:
Pancreatic cancer
Borderline resectable pancreatic cancer
Locally advanced pancreatic cancer
Neoadjuvant chemotherapy
FOLFIRINOX
Liquid biopsy
Online Access:https://doi.org/10.1186/s12893-025-02938-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12893-025-02938-1

Similar Items